I Vynnychenko
Sumy State University
H-index: 30
Europe-Ukraine
Top articles of I Vynnychenko
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study"[Eur Urol 84 (5)(2023 …
European Urology
2023/11/1
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Journal of Thoracic Oncology
2023/1/1
Corrigendum to" Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study"[Eur …
European urology
2023/11
KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC
International Journal of Cancer
2023/8/1
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a …
Annals of Oncology
2023/3/1
I Vynnychenko
H-Index: 20
Lymph nodes dissection in patients with highly differentiated thyroid cancer
The 11 th International scientific and practical conference “Modern research in world science”(January 29-31, 2023) SPC “Sci-conf. com. ua”, Lviv, Ukraine. 2023. 1579 p.
2023/1/29
Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer
Contemporary Oncology/Współczesna Onkologia
2022/12/30
Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma
Journal of Clinical Oncology
2018/6/1
PL03. 09 IMpower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC
Journal of Thoracic Oncology
2022/9/1
IMpower010: overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC
World Conference on Lung Cancer
2022/8/6
Abstract CT533: Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from …
Cancer Research
2022/6/15
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first …
2019/5/20
80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study
Annals of Oncology
2022/4/1
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction …
Cancers
2022/2/24
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …
The Lancet Oncology
2021/1/1
Mustafa Özgüroğlu
H-Index: 23
Marina Chiara Garassino
H-Index: 41
Zsolt Horváth
H-Index: 4
Robin Cornelissen
H-Index: 16
Jong-Seok Lee
H-Index: 14
Roberta Bartolucci
H-Index: 0
Christian Schulz
H-Index: 20
Tatsuya Yoshida
H-Index: 0
Tetsuji Kawamura
H-Index: 3
Ahmet Demirkazik
H-Index: 11
Eric Schaefer
H-Index: 24
Kyung Hee Lee
H-Index: 7
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
The Lancet
2021/10/9
669P Subsequent therapy following pembrolizumab+ axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Annals of Oncology
2021/9/1
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
The Breast
2021/8/1
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Breast cancer research and treatment
2021/7
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung …
2021/5/20
